These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 12834252)
21. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186 [TBL] [Abstract][Full Text] [Related]
25. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Andrew R; Watson DG; Best SA; Midgley JM; Wenlong H; Petty RK Neurochem Res; 1993 Nov; 18(11):1175-7. PubMed ID: 8255370 [TBL] [Abstract][Full Text] [Related]
26. Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients. Kuhn W; Müller T; Gerlach M; Sofic E; Fuchs G; Heye N; Prautsch R; Przuntek H J Neural Transm (Vienna); 1996; 103(12):1441-5. PubMed ID: 9029411 [TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Parkinson Study Group. Arch Neurol; 1995 Mar; 52(3):237-45. PubMed ID: 7872875 [TBL] [Abstract][Full Text] [Related]
28. Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders. Perschak H; Amsler U; Vischer A; Siegfried J; Cuénod M Hum Neurobiol; 1987; 6(3):191-4. PubMed ID: 2896652 [TBL] [Abstract][Full Text] [Related]
29. Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries. Lakke JP; Teelken AW; vd Voet H; Wolthers BG Adv Neurol; 1987; 45():243-7. PubMed ID: 3825697 [No Abstract] [Full Text] [Related]
30. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296 [TBL] [Abstract][Full Text] [Related]
31. A metabolomics study in aqueous humor discloses altered arginine metabolism in Parkinson's disease. Serrano-Marín J; Marin S; Bernal-Casas D; Lillo A; González-Subías M; Navarro G; Cascante M; Sánchez-Navés J; Franco R Fluids Barriers CNS; 2023 Dec; 20(1):90. PubMed ID: 38049870 [TBL] [Abstract][Full Text] [Related]
32. Behavioral correlates of cerebrospinal fluid amino acid and biogenic amine neurotransmitter alterations in dementia. Vermeiren Y; Le Bastard N; Van Hemelrijck A; Drinkenburg WH; Engelborghs S; De Deyn PP Alzheimers Dement; 2013 Sep; 9(5):488-98. PubMed ID: 23159046 [TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. Espino A; Ambrosio S; Bartrons R; Bendahan G; Calopa M J Neural Transm Park Dis Dement Sect; 1994; 7(3):167-76. PubMed ID: 7710669 [TBL] [Abstract][Full Text] [Related]
34. Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. Iacono RP; Kuniyoshi SM; Ahlman JR; Zimmerman GJ; Maeda G; Pearlstein RD J Neural Transm (Vienna); 1997; 104(4-5):451-9. PubMed ID: 9295177 [TBL] [Abstract][Full Text] [Related]
35. Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. Chia LG; Cheng LJ; Chuo LJ; Cheng FC; Cu JS J Neurol Sci; 1995 Nov; 133(1-2):73-8. PubMed ID: 8583235 [TBL] [Abstract][Full Text] [Related]
36. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa. Manyam BV Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767 [TBL] [Abstract][Full Text] [Related]
37. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Olanow CW; Gauger LL; Cedarbaum JM Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206 [TBL] [Abstract][Full Text] [Related]
39. Tissue concentration changes of amino acids and biogenic amines in the central nervous system of mice with experimental autoimmune encephalomyelitis (EAE). Musgrave T; Tenorio G; Rauw G; Baker GB; Kerr BJ Neurochem Int; 2011 Aug; 59(1):28-38. PubMed ID: 21672584 [TBL] [Abstract][Full Text] [Related]
40. Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Tohgi H; Abe T; Takahashi S; Takahashi J; Hamato H Neurosci Lett; 1993 Sep; 159(1-2):135-8. PubMed ID: 7505410 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]